Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

EXELIXIS, INC.

(EXEL)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/12/2019 11/13/2019 11/14/2019 11/15/2019 11/18/2019 Date
15.34(c) 16.37(c) 16.66(c) 16.51(c) 16.25 Last
2 269 806 3 837 986 4 919 714 2 148 866 766 711 Volume
-1.35% +6.71% +1.77% -0.90% -1.57% Change
More quotes
Financials (USD)
Sales 2019 962 M
EBIT 2019 344 M
Net income 2019 298 M
Finance 2019 1 211 M
Yield 2019 -
Sales 2020 1 020 M
EBIT 2020 349 M
Net income 2020 303 M
Finance 2020 1 562 M
Yield 2020 -
P/E ratio 2019 17,7x
P/E ratio 2020 17,7x
EV / Sales2019 3,96x
EV / Sales2020 3,39x
Capitalization 5 017 M
More Financials
Company
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF... 
Sector
Biotechnology & Medical Research
Calendar
11/19 | 09:10amPresentation
More about the company
Surperformance© ratings of Exelixis, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on EXELIXIS, INC.
11/12EXELIXIS : to Present at the Stifel 2019 Healthcare Conference on November 19, 2..
BU
11/12EXELIXIS : rsquo; Partner Ipsen Announces Health Canada's Approval of CABOMETYX®..
BU
11/07EXELIXIS : rsquo; Collaborator Daiichi Sankyo Announces Positive Results From Ph..
BU
10/30EXELIXIS : 3Q Earnings Snapshot
AQ
10/30EXELIXIS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
10/30EXELIXIS, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
10/30EXELIXIS : Announces Third Quarter 2019 Financial Results and Provides Corporate..
BU
10/17EXELIXIS : to Release Third Quarter 2019 Financial Results on Wednesday October ..
AQ
10/16EXELIXIS : to Release Third Quarter 2019 Financial Results on Wednesday, October..
BU
09/25EXELIXIS : to Present at the 2019 Cantor Global Healthcare Conference on October..
BU
09/03EXELIXIS : to Present at the Morgan Stanley 17th Annual Global Healthcare Confer..
BU
07/31EXELIXIS : 2Q Earnings Snapshot
AQ
07/31EXELIXIS, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
07/31EXELIXIS : Announces Second Quarter 2019 Financial Results and Provides Corporat..
BU
07/17EXELIXIS : to Release Second Quarter 2019 Financial Results on Wednesday, July 3..
BU
More news
News in other languages on EXELIXIS, INC.
02/07EXELIXIS, INC. : Veröffentlichung des Jahresergebnisses
02/07EXELIXIS, INC. : publication des résultats annuels
2018STOCK MARKET PARIS : "Tariff Man" a encore frappé
2018EN DIRECT DES MARCHES : EDF, Ipsen, Nissan, Alstom, Air France, Altran...
2018BIOTECH TIME : Cerenis échoue, Hybrigenics courtisé, Ipsen en phase III
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
Stock Trading Strategies
EXELIXIS, INC. - 05/21
Good timing to go long again
BUY
More Stock Trading Analysis
Sector news : Bio Therapeutic Drugs
11/14BEIGENE : FDA Gives Accelerated Approval to BeiGene's Brukinsa
DJ
11/14Walt Disney soars while Cisco disappoints
11/14THERMO FISHER SCIENTIFIC : Qiagen Shares Surge on Report Thermo Fisher Mulling D..
DJ
11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
DJ
11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
DJ
More sector news : Bio Therapeutic Drugs
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 23,73  $
Last Close Price 16,51  $
Spread / Highest target 112%
Spread / Average Target 43,7%
Spread / Lowest Target 2,97%
EPS Revisions
Managers
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Chief Financial & Accounting Officer, Executive VP
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.-16.07%5 017
GILEAD SCIENCES4.03%82 323
VERTEX PHARMACEUTICALS26.61%53 950
REGENERON PHARMACEUTICALS-7.67%37 702
WUXI APPTEC CO., LTD.81.65%22 459
GENMAB41.12%14 493